Dr. Mohamed Omar presented at the NRG Oncology 2026 Winter Meeting in San Francisco, delivering two talks on THR-based signatures for forecasting clinical outcome and treatment response in breast cancer.

The first presentation was to the Pathology Committee, and the second to the Translational Science Committee, both focusing on our work developing cell-of-origin signatures for risk stratification and therapy response prediction in breast cancer patients.

These presentations highlight ongoing collaborations within NRG Oncology to advance precision approaches for breast cancer management.